Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
Last week, the Biden administration proposed expanding Medicare and Medicaid coverage of new GLP-1 “fat-busting” drugs to people with obesity alone. Currently, the cost of the drugs is only covered ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...